GENinCode PLC Statement re: Silicon Valley Bank (6627S)

TIDMGENI

RNS Number : 6627S

GENinCode PLC

13 March 2023

GENinCode Plc

("GENinCode" or the "Company")

Statement re: Silicon Valley Bank

Oxford, UK. GENinCode Plc (AIM: GENI) is aware of media reports indicating the closure of Silicon Valley Bank ("SVB"). The Company does not hold any cash at SVB and does not have a banking relationship with SVB.

For more information visit www.genincode.com

Enquiries:

 
 GENinCode Plc                                                           www.genincode.com or via Walbrook PR 
 Matthew Walls, CEO 
 Paul Foulger, CFO 
 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                             Tel: +44 (0)20 7710 7600 
 Alex Price / Ben Maddison / Richard Short 
 
   Cenkos Securities Plc (Joint Broker)                                              Tel: +44 (0)20 7397 8900 
 Giles Balleny 
 Dale Bellis / Michael Johnson (Sales) 
 
   Walbrook PR Limited                                         Tel: 020 7933 8780 or genincode@walbrookpr.com 
   Anna Dunphy / Paul McManus / Louis Ashe-Jepson

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

GENinCode tests and technology provide physicians and patients with globally leading preventative care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to prevent cardiovascular disease.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

STRDGGDXDBBDGXD

(END) Dow Jones Newswires

March 13, 2023 03:00 ET (07:00 GMT)

Genincode (LSE:GENI)
Historical Stock Chart
From Apr 2024 to May 2024